WAM
PGNX

Wealthspire Advisors (Maryland)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17
Closed – – 2609
2017
Q3 		$0 Buy
+17
New +$108 ﹤0.01% 2558

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s PGNX Position: Q4 2017 in Review

Wealthspire Advisors (Maryland) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2017, closing a stake of 17 shares.

Wealthspire Advisors (Maryland) first reported a position in PGNX in Q3 2017 and held it in 1 quarter. The position peaked at $0 in Q3 2017. 153 funds tracked by Wall St. Rank hold PGNX as of Q4 2017.

  • Wealthspire Advisors (Maryland) reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 17 Progenics Pharmaceuticals Inc shares in Q4 2017.
  • Wealthspire Advisors (Maryland) first reported a position in Progenics Pharmaceuticals Inc in Q3 2017 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Progenics Pharmaceuticals Inc position peaked at $0 in Q3 2017.
  • 153 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2017.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q4 2017, filed 7 Feb 2018.